Equity
€524,259 ▲ 0.1%
GD Lifescience paid out €503,500 in dividends. That is 100% of the 2025 profit.
GD Lifescience
Lifetime
6 annual accounts with figures on one time axispeak €706,148 (2025)
€706,148▲ 84.5%
peak €504,187 (2025)
€504,187▲ 77.3%
peak €524,259 (2025)
€524,259▲ 0.1%
€410,943▲ 46.7%
Board2 names since 2019
2 directors and 1 other
Documentsfilings and deeds
24-06-202637 days before the deadline
2025micro format
Gross margin from €382,695 to €706,148Result from €284,381 to €504,187Dividend €503,500Debts from €280,203 to €410,943Cash from €192,744 to €622,998
Key points
from the 2025 annual accountsResult
€504,187 ▲ 77.3%
The result rose in 2025 from €284,381 to €504,187.
Turnover
≈ €1.0m estimated
The micro format states no turnover.
Debts
€410,943 ▲ 46.7%
Debts rose by €130,740 in 2025. A dividend stands under other debts on the balance sheet date until it is paid.
Filings
6 annual accounts since 2020
The last five annual accounts were filed 7 to 39 days before the end of the period.
Position in the sector
€504,187
Higher net result than 95% of companies in head offices and management consultancy. Sector median €26,442 · 41,246 companies.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 6,783 companies had the same profile as GD Lifescience has now. Each dot stands for 17 companies, two years later.
96.7%
were still trading
2.7%
stopped another way
0.6%
went bankrupt
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 6,783 companies, not a prediction for GD Lifescience. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Board and ownership
Director, since 07-06-2019
Director, since 07-06-2019
- 100 sharesdeed of 17-06-2019
- 100 sharesdeed of 17-06-2019
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0728464654
Incorporation
Founding capital of €20,000, 200 shares · Founders: (comparant) and (comparant) · Appointments: (director) and (director) · published on 17-06-2019 · Gazette deed
First establishment
Narcissenlaan 8, Overijse
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| GD Lifescience Overijse | €0.9m | €706,148 | 56.1% | - |
| GALEXINE Overijse | €0.9m | €636,062 | 41.8% | - |
| WIDEN ADVISORY Keerbergen | €0.9m | €614,920 | 1.9% | 0 |
| BruNetto Asse | €1.1m | €789,109 | 57.6% | - |
| NOT-R Huldenberg | €1.0m | €676,720 | 2.2% | - |
| SEAMS Asse | €0.8m | €663,997 | 21.7% | - |
| The Service Company Waterloo | €1.0m | €720,287 | 34.2% | 5.5 |
These companies have the same main activity as GD Lifescience: business and other management consultancy (NACE 70200). They are comparable in size and age: total assets between €792,000 and €1.1m, founded between 2018 and 2020.
Official details
Source: KBO- Status
- Active since 13-06-2019Normal situation
- Activity
- Business and other management consultancyNACE 70200
- Establishment unit
- 2.290.284.2223090 Overijse, since 13-06-2019
- Financial year end
- 31 December
- Peppol
- Reachable since 13-01-2026
Annual accounts 2025
- €935,202▲ 16.4%
- Filing
- Filed on 24-06-2026, 37 days before the end of the filing period
Insights on GD Lifescience
GD Lifescience files the micro format. That format states no turnover. The gross margin rose from €195,667 in 2020 to €706,148 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about GD Lifescience
- What is the company number of GD Lifescience?
- The company number of GD Lifescience is 0728.464.654. The VAT number is the same number with BE in front: BE 0728.464.654.
- Where is GD Lifescience based?
- The registered office is at Narcissenlaan 8, 3090 Overijse.Company details
- What does GD Lifescience do?
- According to the KBO register, the main activity is business and other management consultancy (NACE 70200).
- What is the legal form of GD Lifescience?
- GD Lifescience is a private limited company (BV).
- When was GD Lifescience founded?
- GD Lifescience was founded on 13-06-2019.
- Is GD Lifescience still active?
- Yes, GD Lifescience is an active enterprise in the KBO register.
- What is the turnover of GD Lifescience?
- The turnover in financial year 2025 is ≈ €1.0m. This figure is estimated from the gross margin of €706,148 and 95 comparable companies (NACE 70200). It probably lies between €840,000 and €1.8m.Financials
- Is GD Lifescience profitable?
- In financial year 2025, GD Lifescience made a profit of €504,187.
- Where can I find the annual accounts of GD Lifescience?
- GD Lifescience filed 6 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of GD Lifescience due?
- GD Lifescience must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.